Peptide detail

Dihexa

Dihexa is a synthetic peptide derived from angiotensin IV that was developed at Washington State University as a potential treatment for neurodegenerative conditions like Alzheimer's disease. It has been dubbed a 'neurogenic nootropic' for its remarkable ability to stimulate neuronal growth and connectivity. Dihexa works by enhancing the activity of hepatocyte growth factor (HGF) and its receptor c-Met, a system critical for neurogenesis and synaptogenesis. Research suggests it's approximately 7 million times more potent than BDNF (brain-derived neurotrophic factor) at promoting neuronal growth and connectivity. In animal studies, Dihexa has demonstrated the ability to reverse cognitive impairment caused by various forms of brain damage and neurotoxicity. It has shown potential for treating conditions characterized by neuronal loss or dysfunction, including Alzheimer's disease, Parkinson's disease, and stroke-related damage. Unlike many nootropics that primarily modulate neurotransmitters, Dihexa focuses on structural changes in the brain, potentially offering more fundamental and lasting cognitive benefits.